A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis

NCT06786507 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis (UC)

Interventions

DRUG: Ustekinumab 90 mg
DRUG: Infliximab

Sponsor

Helwan University